Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Diffuse large B-cell lymphoma (DLBCL) exhibits significant biologic heterogeneity.
• A subset of DLBCL patients presents with poor prognosis and characteristics similar to Burkitt lymphoma.
• Current cytogenetic methods for identifying high-risk DLBCL, such as double-hit lymphomas, require refinement for better clinical utility.

Purpose of the Study:

• To define a molecular high-grade (MHG) group in DLBCL using a gene expression-based classifier.
• To compare the prognostic significance of the MHG group with existing biomarkers.
• To explore the molecular pathology and validate findings in independent datasets.

Main Methods:

• A gene expression-based classifier was applied to 928 DLBCL patients from a clinical trial.
• Targeted sequencing of 70 genes was performed on 400 patients.
• Molecular pathology was investigated using gene expression signature databases and validated in an independent dataset.

Main Results:

• The MHG group comprised 9% of patients and was characterized by a proliferative phenotype.
• Progression-free survival at 36 months was significantly lower in the MHG group (37%) compared to others (72%) after R-CHOP therapy.
• MYC-rearranged and double-hit lymphomas were over-represented in MHG, but MHG encompassed a broader group.

Conclusions:

• The MHG classification defines a biologically coherent high-grade B-cell lymphoma group with distinct molecular features and poor clinical outcomes.
• MHG effectively doubles the size of the previously defined poor-prognosis, double-hit lymphoma group.
• Patients with MHG may benefit from intensified chemotherapy or novel targeted therapies.